Dansk | English


South San Francisco, February 9 – – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today that the results of its recently completed EMERGE trial, a Phase 2a randomized, double-masked, multi-dose study of the drug candidate ICON-1 in wet Age-Related Macular Degeneration (AMD), will be presented for the first time at the Angiogenesis, Exudation, and Degeneration meeting in Miami, FL on Saturday February 11. The trial design included assessment of outcomes specifically designed to measure lesion growth and leakage, both hallmarks of disease progression in AMD. The EMERGE trial was a six-month, active-controlled, multi-center study of 88 patients with newly diagnosed disease. Iconic previously completed an 18-subject Phase 1 clinical trial in neovascular AMD, which demonstrated safety and preliminary evidence of potential biologic activity

a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialisis.

San Diego, USA and Palma, Spain, January 23, 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).

Vtesse Announces Dosing of First Patient in Australia in Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

Clinicians Continuing to Enroll Children with NPC at Trial Sites in the United States, Germany, the United Kingdom, France, Spain, and Turkey 

GAITHERSBURG, Md., Jan. 10, 2017 /PRNewswire/ -- Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that clinicians have dosed the first trial participants in Australia in the company's global, pivotal clinical trial of investigational drug VTS-270 for Niemann-Pick Type C1 disease (NPC). 

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

Funding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform.

LEXINGTON, Mass., Jan. 4, 2017 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round. The investment was co-led by OrbiMed and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma). In addition to OrbiMed and Sun Pharma, existing investors 5AM Ventures and Lundbeckfond Ventures participated in the financing. This Series B investment will support the development of the operational and commercial infrastructure to bring Furoscix™ and the sc2Wear™ Infusor to market in the United States.

Vtesse Announces Appointment of Jason Meyenburg as Chief Commercial Officer

-New position created to help provide access to VTS-270 for children with Niemann-Pick Type C1 disease upon approval by regulatory authorities

GAITHERSBURG, Md., Jan. 4, 2017 /PRNewswire/ -- Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today the appointment of Jason Meyenburg as Chief Commercial Officer. Mr. Meyenburg joins the company from Alexion Pharmaceuticals, Inc., where he most recently served as Senior Vice President, Commercial Operations, The Americas.

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors

DECEMBER 20th, 2016 – NEW YORK and OXFORD, UK - Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Björn Westberg to join BONESUPPORT™ as Chief Financial Officer

Lund, Sweden, 21 December 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that Björn Westberg is to join the Company as Chief Financial Officer and Director in early 2017.

Mr Westberg brings nearly 30 years’ finance and management experience to BONESUPPORT. He joins from Recipharm AB (publ) - one of the largest pharmaceutical contract manufacturers in the world - where he has been CFO since 2007. Prior to this he was CFO of the listed (Nasdaq Stockholm) software company Jeeves (2001-2007), and before that he held senior roles at AstraZeneca, among those Finance Director ISMO Northern Europe and Controller in Astra Japan. 

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board

BONESUPPORT confirms election of Dr. Håkan Björklund as Chairman of the Board. Tone Kvåle, CFO of Nordic Nanovector, elected as a new Board Member. 

Lund, Sweden, 16 December 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces, that Dr. Håkan Björklund has been confirmed as Chairman and that  Ms. Tone Kvåle has been elected as a  new Board Member. The appointments were made at an EGM held on 15 December 2016.

Dr. Björklund is Partner of Tellacq AB, a private investment firm. He joined the BONESUPPORT Board in September 2016 in conjunction with the Company’s $37 million (SEK 315 million) financing, which was led by Tellacq. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners.

Tone Kvåle joins as a Board Member and Head of the Audit Committee. She is currently Chief Financial Officer of Nordic Nanovector, an Oslo-listed biopharmaceutical company, and has more than 20 years’ biotech industry experience. Prior to joining Nordic Nanovector, she was CFO of NorDiag, Kavli Holding and Dynal Biotech, and has held senior management positions at Invitrogen, Life Technologies and ThermoFisher (US). Ms. Kvåle has a diploma in Finance & Administration from Harstad University College.

Richard Davies, CEO of BONESUPPORT, said: “I am extremely happy that Håkan has been elected Chairman and that Tone will be joining the Board. This is an exciting period for BONESUPPORT following our recent $37 million (SEK 315 million) financing. We are now focused on building further additional shareholder value by growing  sales of our current CERAMENT products, generating further data highlighting the clinical and health economic benefits these products deliver and progressing our pipeline. I am confident that Håkan’s and Tone’s experience will be valuable in helping us achieve our strategic goals.”

Dr. Björklund said: “I look forward to working with the management team and the Board to deliver BONESUPPORT’s potential to become a global leader in the management and treatment of bone disease based on the unique properties of its CERAMENT platform.”

Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline

Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score
compared to placebo after eight weeks of treatment with a favorable safety profile

Eczema is a chronic, inflammatory skin condition affecting millions of children and adults worldwide1 with an unmet need for effective and safe oral treatments
Bonesupport - Richard Davies Wins “Best CEO in the Biomaterials Industry” Award from European CEO Magazine

Lund, Sweden, 13 December, 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, is pleased to announce that its CEO Richard Davies has won the “Best CEO in the Biomaterials Industry” award. The award was presented by European CEO Magazine based on Mr. Davies’ track record at the forefront of major new healthcare trends and the continuing success of BONESUPPORT™ under his leadership.

Mr. Davies became CEO of BONESUPPORT in January 2016, following nearly four years spent at Hospira, where he served as Chief Commercial Officer. While at Hospira, he drove growth, globalization and modernization across the business. Hospira was acquired by Pfizer at the end of 2015. Prior to Hospira, Mr. Davies spent nine years in increasingly senior leadership positions at Amgen in Europe, Australia and the U.S. His roles included leadership of the U.S. Inflammation sales group, which commercialized Enbrel® (etanercept), the most prescribed biologic medicine in the U.S. at that time. Mr. Davies began his career at Eli Lilly, spending 13 years in increasingly senior positions. 

Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste